



April 5, 2018

***RE: Support for XORTX Therapeutics Inc. PKD programs and Clinical Studies***

Dear Allen,

I am writing to express the PKD Foundation's support and enthusiasm for the proposed programs that XORTX Therapeutics Inc. is undertaking. Your company's efforts to develop treatments for autosomal dominant polycystic kidney disease (ADPKD) are important and greatly needed. We welcome your interaction with the Polycystic Kidney Disease Foundation. As you know, we are the only organization in the U.S. solely dedicated to finding treatments and a cure for ADPKD, and have prioritized efforts to improve the lives of those affected by this disease.

The PKD Foundation recognizes that XORTX Therapeutics Inc. is leading the way in developing treatments for progressive kidney disease and importantly rare diseases such as ADPKD. The evidence suggesting that uric acid is acting to negatively affect the health and outcomes of patients with polycystic kidney disease merits further exploration in rigorous, well designed clinical trials, as does characterizing the benefits of lowering and managing uric acid levels in ADPKD patients.

We are highly motivated to assist XORTX Therapeutics Inc. in your efforts to develop therapies that would improve the quality of life for patients and to extend the time that kidneys remain functional. We can offer assistance by facilitating contacts with individuals and our membership base. Our proposed collaboration would allow XORTX to establish and optimize the development of your lead therapy. We believe that the combination of the PKD Foundation's and XORTX's scientific expertise may enable an entirely new class of highly active and potentially important treatments for patients for whom current biopharmaceutical approaches have had limited success.

We would encourage XORTX Therapeutics to begin discussions with both our ADPKD and ARPKD constituents, and to consider the clinical impact of this mechanism of disease progression and alignment with your therapeutic approach.

Therefore, on behalf of the PKD Foundation it is my pleasure to confirm our support XORTX Therapeutics efforts on behalf of PKD patients in the US and around the world. We look forward to working with you to reach our ultimate goal of successfully bringing new therapeutics to patients.

Sincerely,

**Dr. David Baron**, Chief Scientific Officer